An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors
Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Sponsor: Hoffmann-La Roche
Enrolling: Male and Female Patients
IRB Number: AAAS5758
U.S. Govt. ID: NCT03708328
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to determine the doses of RO7121661 that can be administered safely to patients and what the side effects of RO7121661 are. In addition, how RO7121661 affects your body and, in particular, your tumor will be measured. The study also aims to investigate if RO7121661 can slow down or stop the growth of tumors in patients with solid tumors (lung cancer).
This study is closed
Brian Henick, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have advanced and/or metastatic solid tumors in your lungs? Yes No
Have you progressed on a previous cancer therapy, or no effective therapy currently exists for you? Yes No
Are you willing to come to make extra visits to the doctor and undergo extra tests and procedures? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator